Study guide
8.2 Localized RCC: Nephron-Sparing Surgery & Radical Nephrectomy
FEBU Part 1 Written European Board of Urology
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Strategy
1.1 FEBU Part 1 Examination Structure & Logistics 1.2 EAU Guidelines Framework & Standard Setting 1.3 Clinical Decision-Making & MCQ Strategy 1.4 Professionalism and Safe Practice
2 Chapter 2: Genitourinary Anatomy & Renal Physiology
2.1 Upper Tract Anatomy & Retroperitoneal Relationships 2.2 Lower Urinary Tract Anatomy & Neuroanatomy 2.3 Renal Physiology, Glomerular Filtration & Acid-Base Balance
3 Chapter 3: Urological Pharmacology & Diagnostic Imaging
3.1 Lower Urinary Tract Pharmacotherapy 3.2 Antimicrobial Stewardship & Perioperative Care 3.3 Diagnostic Modalities: Ultrasound, CT, mpMRI & Nuclear Medicine
4 Chapter 4: Prostate Cancer: Diagnosis & Risk Stratification
4.1 PSA Kinetics, Biomarkers & Risk Assessment 4.2 Multiparametric MRI (PI-RADS) & Biopsy Strategies 4.3 Histopathological Grading (ISUP Gleason) & Staging
5 Chapter 5: Prostate Cancer: Localized & Advanced Management
5.1 Active Surveillance & Watchful Waiting 5.2 Radical Prostatectomy & Radiation Therapy 5.3 Biochemical Recurrence & Salvage Therapies 5.4 Metastatic & Castration-Resistant Prostate Cancer (CRPC)
6 Chapter 6: Bladder Cancer: Non-Muscle Invasive (NMIBC)
6.1 TURBT Technique & Pathological Staging 6.2 EAU Risk Stratification for NMIBC 6.3 Intravesical Chemotherapy & BCG Immunotherapy
7 Chapter 7: Muscle-Invasive Bladder Cancer & Upper Tract Urothelial Carcinoma
7.1 Muscle-Invasive Bladder Cancer (MIBC) Staging & Neoadjuvant Therapy 7.2 Radical Cystectomy & Urinary Diversion 7.3 Upper Tract Urothelial Carcinoma (UTUC)
8 Chapter 8: Renal Cell Carcinoma & Adrenal Neoplasms
8.1 Histological Subtypes, Genetics & Staging of RCC 8.2 Localized RCC: Nephron-Sparing Surgery & Radical Nephrectomy 8.3 Metastatic RCC & Targeted / Immunotherapy Regimens 8.4 Adrenal Masses & Incidentalomas
9 Chapter 9: Testicular Germ Cell Tumours & Penile Cancer
9.1 Testicular Cancer Diagnosis, Staging & Tumour Markers 9.2 Management of Seminoma (Stage I to Metastatic) 9.3 Management of Non-Seminoma (Stage I to Metastatic) 9.4 Penile Cancer: Staging, Organ-Sparing & Lymphadenectomy
10 Chapter 10: Benign Prostatic Hyperplasia & Lower Urinary Tract Symptoms
10.1 BPH Pathophysiology, Natural History & Clinical Evaluation 10.2 Medical Management of Male LUTS / BPO 10.3 Interventional & Surgical Management of BPO
11 Chapter 11: Functional Urology, Incontinence & Neuro-Urology
11.1 Urinary Incontinence in Men and Women, Fistulae & Urethral Diverticula 11.2 Overactive Bladder, Bladder Pain Syndrome & Pelvic Organ Prolapse 11.3 Neurogenic Lower Urinary Tract Dysfunction (NLUTD) 11.4 Urodynamic Studies: Indications, Technique & Interpretation
12 Chapter 12: Urolithiasis: Evaluation & Medical Management
12.1 Stone Pathophysiology & Risk Factors 12.2 Metabolic Evaluation & Dietary/Medical Stone Prevention 12.3 Acute Ureteric Colic & Medical Expulsive Therapy
13 Chapter 13: Endourology & Interventional Stone Management
13.1 Shock Wave Lithotripsy (SWL) 13.2 Ureteroscopy (URS) & Retrograde Intrarenal Surgery (RIRS) 13.3 Percutaneous Nephrolithotomy (PCNL) & Endourological Safety
14 Chapter 14: Infections, Andrology & Male Infertility
14.1 Localised & Systemic UTIs, Pyelonephritis, Urosepsis & Specific Infections 14.2 Prostatitis, Epididymo-Orchitis & Fournier Gangrene 14.3 Male Infertility: Evaluation & Surgical Management 14.4 Erectile Dysfunction, Peyronie Disease, Priapism & Gender-Affirming Surgery
15 Chapter 15: Paediatric Urology, Trauma & Renal Transplantation
15.1 Cryptorchidism, Hypospadias & PUJO 15.2 Vesicoureteral Reflux, Posterior Urethral Valves & Nocturnal Enuresis 15.3 Genitourinary Trauma: Kidney, Bladder & Urethra 15.4 Renal Failure, Dialysis Indications & Renal Transplantation
8.2 Localized RCC: Nephron-Sparing Surgery & Radical Nephrectomy
Key Takeaways Explain This Topic AI
Partial nephrectomy (PN / nephron-sparing surgery) is the established gold standard for clinical T1a renal tumours (≤4 cm) and the preferred modality for clinical T1b tumours (4–7 cm) whenever technically feasible, offering equivalent oncological survival with superior long-term renal function preservation.
Indications for partial nephrectomy are categorized into absolute (anatomical or functional solitary kidney, bilateral synchronous tumours), relative (pre-existing CKD, diabetes, hypertension, hereditary predispositions), and elective (localized unilateral mass with healthy contralateral kidney).
Minimize warm ischemia, commonly aiming for under 20–25 minutes while preserving perfused parenchyma. Longer clamping may justify renal hypothermia; neither warm nor cold ischemia has a universally safe time limit.
Surgical margins in partial nephrectomy require complete histological clearance (R0); the microscopic width of the negative margin does not correlate with recurrence, and tumour enucleation along the fibrous pseudocapsule provides equivalent oncological control to standard sharp wedge resection.
Omit routine ipsilateral adrenalectomy when there is no evidence of adrenal involvement, and routine LND in organ-confined cN0 RCC. Remove clinically enlarged nodes for staging and prognosis; a survival benefit from LND is unproven.
Last updated: November 2026
8.2 Localized RCC: Nephron-Sparing Surgery & Radical Nephrectomy
The surgical management of localized renal cell carcinoma (T1–T2 N0 M0) has undergone a major paradigm shift over the past two decades. Historically, open radical nephrectomy as described by Robson represented the universal standard for all renal masses. Modern urological guidelines, led by the European Association of Urology (EAU), emphasize that nephron-sparing surgery (NSS) via partial nephrectomy is the reference standard for small renal tumours. Preserving vascularized renal parenchyma reduces loss of renal function while maintaining oncological control in suitable T1 tumours. A cardiovascular or overall survival advantage over radical nephrectomy has not been established by randomized evidence.
1. Indications for Partial Nephrectomy (NSS)
Surgical indications for partial nephrectomy are stratified into three distinct clinical categories:
Absolute Indications
Clinical Situations : Situations where preserving functioning renal tissue is essential to avoid renal replacement therapy, particularly if both kidneys would otherwise require removal:
Anatomical solitary kidney (previous contralateral nephrectomy, unilateral renal agenesis).
Functionally solitary kidney (contralateral kidney severely atrophic, non-functioning, or dysplastic).
Bilateral synchronous renal cortical tumours.
Relative Indications
Clinical Situations : Conditions where the patient has a functioning contralateral kidney, but underlying systemic or genetic pathologies place future contralateral renal function at high risk:
Pre-existing chronic kidney disease (baseline eGFR < 60 mL/min/1.73 m² or proteinuria).
Chronic systemic diseases associated with progressive nephrosclerosis (type 1 or type 2 diabetes mellitus, severe renovascular hypertension, recurrent nephrolithiasis, chronic glomerulonephritis).
Hereditary RCC syndromes (VHL, BHD, HPRC) where the patient faces a lifelong risk of developing metachronous contralateral renal neoplasms.
Elective Indications
Clinical Situations : A localized unilateral renal mass (clinical T1a, and select clinical T1b) in a patient with a completely normal contralateral kidney, normal baseline serum creatinine and eGFR, and no systemic risk factors for renal deterioration.
Evidence Base : EORTC 30904 randomized 541 patients with tumours ≤5 cm and a normal opposite kidney. Cancer-specific outcomes were excellent with both operations. PN reduced eGFR <60, but differences in advanced renal failure were uncertain; it did not improve overall survival. The prematurely closed trial does not prove a survival advantage for PN.
2. Technical Nuances & Renal Ischemia Dynamics
Preserving post-resection renal function depends on three determinants: the quantity of preserved parenchymal volume, baseline nephron reserve, and the duration/nature of intraoperative renal ischemia.
Ischemia Types & Renal Protection
Warm Ischemia (WIT) : The renal artery (with or without the renal vein) is clamped at body temperature (37°C) using atraumatic vascular bulldog clamps.
Practical Goal : Keep warm ischemia as short as feasible, commonly aiming for <20–25 minutes . Prolonged clamping increases renal injury risk, but there is no sharp boundary at which irreversible damage invariably occurs. Baseline function and preserved parenchymal volume also matter.
Cold Ischemia (CIT) : Following vascular clamping, the kidney is surrounded by crushed ice slush (surface hypothermia) to cool the renal parenchyma to 15–20°C, markedly reducing cellular metabolism and ATP depletion.
Role : Hypothermia permits longer clamping when complex resection or reconstruction is anticipated. It reduces ischemic injury but does not guarantee safety at a fixed duration.
Off-Clamp / Selective Clamping : Off-clamp surgery avoids hilar clamping; selective clamping limits ischemia to the supplied territory, sometimes guided by Doppler or indocyanine-green fluorescence. These are selected techniques, not routine requirements; CLOCK found no functional advantage for off-clamp surgery in patients with two kidneys and normal baseline function.
Surgical Margins & Tumour Enucleation
Margin Status : The primary oncological goal of partial nephrectomy is an R0 resection (complete histological tumour excision with microscopically negative margins). Extensive registry data confirm that the width of the negative parenchymal margin does not influence recurrence rates; a negative margin of 0.5 mm or 1 mm confers identical recurrence-free survival to a margin of 5 mm.
Enucleation vs Resection : Tumour enucleation involves blunt microdissection precisely along the natural fibrous pseudocapsule that surrounds most renal cortical neoplasms, preserving the maximum rim of surrounding healthy parenchyma. Enucleation achieves oncological outcomes equivalent to traditional sharp wedge resection with a wider parenchymal rim, while preserving adjacent renal tissue; ischemia and complication outcomes also depend on tumour anatomy and technique.
Objective Nephrometry Scoring Systems
Nephrometry scoring systems provide standardized, reproducible radiological metrics to quantify tumour complexity, anticipate perioperative complications, and guide the choice between partial and radical nephrectomy:
The R.E.N.A.L. Nephrometry Score
(R)adius : Maximal tumour diameter (≤4 cm = 1 pt; >4 to <7 cm = 2 pts; ≥7 cm = 3 pts).
(E)xophytic/Endophytic Properties : Percentage of tumour projecting beyond the renal cortical contour (≥50% exophytic = 1 pt; <50% exophytic = 2 pts; entirely endophytic = 3 pts).
(N)earness to Collecting System or Sinus : Shortest distance to the collecting system or renal sinus (≥7 mm = 1 pt; >4 to <7 mm = 2 pts; ≤4 mm = 3 pts).
(A)nterior / Posterior Descriptor : Qualitative descriptor (A = anterior, P = posterior, X = indeterminate).
(L)ocation Relative to Polar Lines : Location relative to upper and lower renal polar lines (entirely above/below polar lines = 1 pt; crossing a polar line = 2 pts; >50% across a polar line, crossing the axial midline, or entirely between polar lines = 3 pts). Add the separate suffix h when the mass abuts the main renal artery or vein.
Complexity Stratification : Low complexity (4–6 points), Moderate complexity (7–9 points), High complexity (10–12 points). High complexity scores correlate with longer WIT, higher blood loss, increased risk of urine leak, and higher conversion rates to radical nephrectomy.
The P.A.D.U.A. Score
Evaluates similar anatomical parameters: longitudinal polar location, exophytic rate, renal rim relationship, renal sinus involvement, collecting system infiltration, and tumour diameter.
3. Radical Nephrectomy (RN) & Extended Boundaries
Radical nephrectomy involves surgical excision of the kidney along with surrounding perinephric adipose tissue within an intact Gerota's fascia.
Indications for Radical Nephrectomy
T2 tumours unsuitable for PN, and resectable locally advanced T3–T4 tumours. Selected T2 lesions in a solitary kidney or CKD may still be treated with PN if feasible.
Localized tumours where partial nephrectomy is technically non-feasible due to unfavourable central/hilar location, complete endophytic position in a high-complexity setting, or severe invasion into major intrarenal vascular branches.
Extensive parenchymal replacement where residual nephron mass would provide negligible function.
Adrenalectomy: When is it Indicated?
Routine ipsilateral adrenalectomy was historically included in the Robson triad of radical nephrectomy. Modern guideline consensus is unequivocal: routine ipsilateral adrenalectomy offers no oncological benefit and exposes patients to unnecessary surgical risk and potential adrenal insufficiency.
Indications for Adrenalectomy : Clinical evidence of adrenal involvement on imaging or at surgery, including suspected direct invasion or an adrenal metastasis appropriate for resection.
Regional Lymph Node Dissection (LND)
The EORTC 30881 Evidence : This randomized trial demonstrated that routine regional retroperitoneal lymphadenectomy in patients with clinically normal lymph nodes (cN0) does NOT improve overall survival or time to progression.
Guideline Consensus : Routine LND is not recommended in localized cN0 disease. Remove clinically enlarged, suspicious nodes detected on imaging or at surgery for staging and prognosis. High-risk primary features alone do not establish a survival benefit from routine extended LND in cN0 disease.
- 4. Alternative Modalities: Thermal Ablation & Active Surveillance
- Thermal Ablation
An option for selected cT1 lesions requiring treatment in patients unfit for surgery. EAU advises against routinely using RFA for tumours >3 cm or cryoablation for tumours >4 cm; biopsy must precede ablation.
Cryoablation : Utilizes hollow needles delivering pressurized argon gas to induce rapid expansion and cooling (Joule-Thomson effect), generating an intra-tumoral ice ball reaching temperatures < -40°C . Alternating cycles of freezing and thawing induce intracellular ice crystal formation, cell membrane rupture, vascular stasis, and coagulative necrosis. Real-time monitoring with ultrasound or non-contrast CT allows precise visualization of the ice ball.
Radiofrequency Ablation (RFA) : High-frequency alternating electrical current generates ionic agitation, friction, and hyperthermic thermal coagulation ( > 50°C to 100°C ), leading to protein denaturation and irreversible tissue destruction.
Oncological Outcomes : Comparative evidence suggests more local recurrence after thermal ablation than PN, but study quality and follow-up limit precise comparisons. Ablation may reduce perioperative morbidity; selected local failures can undergo repeat treatment.
Active Surveillance (AS)
Active surveillance uses serial imaging with delayed treatment for progression. A commonly used schedule is every 6 months for two years, then annually, adapted to risk. Watchful waiting instead focuses on symptoms when later curative treatment would not be appropriate.
Natural History of Small Renal Masses (SRMs) : Many cT1a masses grow slowly. A DISSRM growth analysis reported a median of 0.09 cm/year ; growth varies and does not reliably distinguish all benign from malignant lesions. Metastatic progression is uncommon in selected surveillance cohorts.
Triggers for Active Intervention :
Rapid tumour growth kinetics (> 5 mm per year).
Increasing size, with >4 cm a DISSRM intervention trigger; decisions also reflect histology, anatomy and patient fitness.
Patient preference or improvement in medical fitness.
5. Renal Mass Biopsy (RMB)
Historically avoided due to exaggerated fears of malignant tumour tract seeding, percutaneous renal mass biopsy (core needle biopsy, 18-gauge) is now widely integrated into urological clinical pathways.
Clinical Indications for RMB
Prior to Thermal Ablation : Obtain histology in a separate session before , not during, ablation. Grade assessment is less reliable than histotype because of sampling heterogeneity.
Prior to Active Surveillance : Consider biopsy when histology would change surveillance or treatment decisions. A reassuring sample cannot exclude all unsampled high-grade or sarcomatoid components.
Ambiguous Renal Lesions : To differentiate renal neoplasms from non-neoplastic masses, infectious lesions, renal lymphoma, or suspected solitary metastasis from an extra-renal primary (lung, colon, melanoma).
Advanced / Metastatic RCC : To confirm histology and guide first-line systemic targeted/immunotherapy regimens.
Diagnostic Accuracy & Complication Profile
Accuracy : Sensitivity and specificity exceed 90% to 95% for core needle biopsies. However, biopsy exhibits modest accuracy (~60–70%) for determining exact WHO/ISUP nuclear grade due to intra-tumoral grade heterogeneity.
Safety : Major complications (perirenal hematoma requiring transfusion or embolization) occur in <1%. Clinically significant needle-tract seeding is very rare; use a coaxial technique. Histological tract deposits have been reported, so the risk is not zero.
6. Surgical Modality Decision Matrix
Management Modality Primary Clinical Indications Oncological Control (5-Year CSS) Impact on Renal Function Major Complications & Limitations
Partial Nephrectomy (PN) cT1a (gold standard), select cT1b; absolute/relative indications for NSS Excellent (>95–97%); equivalent to radical nephrectomy Maximal preservation of nephron mass; reduces renal function loss; survival advantage unproven Urine leak (1–3%), secondary hemorrhage/pseudoaneurysm (1–2%), warm ischemia injury
Radical Nephrectomy (RN) T2 unsuitable for PN; resectable T3–T4; complex T1 unsuitable for PN Depends on stage, grade and histotype Sacrifices entire ipsilateral kidney; increases risk of de novo CKD Low surgical re-exploration rate; overtreatment if applied indiscriminately to small tumours
Thermal Ablation (Cryo / RFA) cT1 requiring treatment in patients unfit for surgery; size limits differ by technique Good local control in selected lesions; more local failure than PN Minimal parenchymal destruction; low impact on baseline eGFR Mandatory pre-treatment core biopsy; risk of urothelial stricture if near collecting system
Active Surveillance (AS) Selected cT1a with delayed treatment appropriate; consider watchful waiting if treatment will never be suitable High CSS and low metastatic risk in selected cohorts Avoids immediate treatment-related renal injury Requires compliant radiological follow-up; psychological anxiety regarding untreated cancer